SEL113

SEL113 is an early-stage drug candidate referenced in patent literature as one of multiple example therapeutic agents for treating posterior ocular and other disorders, including anti-inflammatory and possibly steroidal or NSAID-like molecules, but without any clearly disclosed, unique active ingredient, structure, or defined pharmacological profile specific to the code SEL113 itself. Public sources list SEL113 only as a pipeline code associated with Selvita’s oncology and autoimmune disorder programs and as a hypothetical/example drug name in broad method patents for ocular therapy, with no confirmed mechanism of action, target, clinical indication, structure, or development status that can be uniquely attributed to SEL113 as a distinct molecule.